BioMarin Pharmaceutical Inc., a leading global biotechnology entity, unveiled that its drug, VOXZOGO (vosoritide), has received the green light from the U.S. Food and Drug Administration (FDA) to enhance linear growth in pediatric patients of all ages with open epiphyses (growth plates) suffering from achondroplasia. Key Highlights from the Approval Previously, the drug’s indication was […]
Pfizer acquisition of Therachon : US pharma giant Pfizer has completed its previously announced acquisition of Swiss biotech company Therachon, which is focused on rare diseases, in a deal worth up to $810 million, as per the latest pharma acquisition news. The clinical-stage Therachon is currently engaged in developing treatment of achondroplasia and short bowel […]
